A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/05/2002	WO2002096200A1 Conjugated nonadecadienoic acid compositions
12/05/2002	WO2002087557A8 Method for treating retina or photoreceptor degeneration
12/05/2002	WO2002083675A3 Inhibitors of akt activity
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002080854A3 Compositions and methods for the prevention and treatment of human prostate cancer
12/05/2002	WO2002078693A3 N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
12/05/2002	WO2002078633A8 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
12/05/2002	WO2002078464A3 Food item for increasing cognitive capacity
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002074036A3 Substituted benzopyranones as telomerase inhibitors
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002066009A9 Modulated release particles for aerosol delivery
12/05/2002	WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
12/05/2002	WO2002064189A3 Radiation cross-linked hydrogels
12/05/2002	WO2002064124A3 Medicament formulation containing a muscarinic agonist
12/05/2002	WO2002063954A3 USE OF β-LACTAMASE INHIBITORS AS NEUROPROTECTANTS
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002060426A3 Compounds regulating cell proliferation and differentiation
12/05/2002	WO2002059116A3 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
12/05/2002	WO2002056902A3 Ccr5 antagonist and dp-178 polypeptide for treating viral infections
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002051819A3 Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
12/05/2002	WO2002049619A3 Induced phase transition method for the production of microparticles containing hydrophilic active agents
12/05/2002	WO2002049590A3 Antiperspirant products
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002034234A3 Methylphenidate modified release formulations
12/05/2002	WO2002028351A9 Recombinant mucin binding proteins from steptococcus pneumoniae
12/05/2002	WO2002022106A3 Stable ophthalmic preparation
12/05/2002	WO2002011707A3 Drugs for incontinence
12/05/2002	WO2002009685A1 Preparation with vascular protective and anti-oxidative effect and use thereof
12/05/2002	WO2002009637A3 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001093909A3 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	WO2001091734A3 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
12/05/2002	WO2001064949B1 Diagnostics and therapeutics for glaucoma
12/05/2002	WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002	WO2001032685A9 Gene expression directed by a super-psa promoter
12/05/2002	WO2001019408A9 Nucleic acids encoding polyepitope polypeptides
12/05/2002	US20020183808 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
12/05/2002	US20020183764 Embolic materials
12/05/2002	US20020183746 Spine distraction implant
12/05/2002	US20020183687 Adhesion prevention and an endoscopic insufflation system therefor
12/05/2002	US20020183532 Bioavailable prodrugs of androgenic steroids and related method
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183523 Cis-substituted aminocyclopropane derivative
12/05/2002	US20020183518 Use for treatment of human and animal disorders, for purification of proteins or glycoproteins, and in diagnosis
12/05/2002	US20020183515 Asymmetric synthesis of a key intermediate for making benazepril and analogues thereof
12/05/2002	US20020183514 Useful in the treatment and control of solid tumors
12/05/2002	US20020183513 Tricyclic alkylhydroxamate derivatives
12/05/2002	US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183500 Nucleotide sequence coding polypeptide for use in the treatment, diagnosis, classification and imaging of lung cancer
12/05/2002	US20020183400 Composition for topical application comprising at least one hydroxystilbene and at least one polyol to solubilize the hydroxystilbene
12/05/2002	US20020183399 Method and compositions for treating rosacea
12/05/2002	US20020183398 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
12/05/2002	US20020183396 Local anesthetic methods and kits
12/05/2002	US20020183395 Methods for treating hyperactive gastric motility
12/05/2002	US20020183394 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
12/05/2002	US20020183391 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
12/05/2002	US20020183390 Administration of a D-serine transport inhibitor (serine dodecylamide, alanine dodecylamide or glycyldodecylamide) sufficient to enhance (N-methyl-D-aspartate) receptor mediated neurotransmission in vivo for psychological disorder
12/05/2002	US20020183389 Preferably at least 95%, is in the form of eicosapentaenoic acid (EPA), and less than 5%, and preferably less than 3% is in the form of docosahexaenoic acid (DHA); useful for treating psychological and nervous system disorders
12/05/2002	US20020183388 Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
12/05/2002	US20020183387 Topically applying to the affected area in the nail a lower alcohol and a lower carboxylic acid to treat the bacterial or fungal infection
12/05/2002	US20020183385 Administering a therapeutically effective amount of arsenic compounds to a mammal for treating solid tumor
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183383 Pharmaceutical compositions
12/05/2002	US20020183382 For therapy of liver injury resulting from hepatic steatosis or steatohepatitis
12/05/2002	US20020183381 Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
12/05/2002	US20020183380 Administering anti-microtubule compound-containing, pharmaceutically acceptable formulation wherein anti-microtubule compound is paclitaxel for therapy and prophylaxis of surgical adhesions
12/05/2002	US20020183379 Kits for determining risk of Alzheimer's disease
12/05/2002	US20020183378 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
12/05/2002	US20020183377 Use of melatonin for treating androgenetic and diffuse alopecia
12/05/2002	US20020183376 Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
12/05/2002	US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002	US20020183373 Use of amino-isoxazolidone compounds for improvement of lexical priming
12/05/2002	US20020183372 Use of amino-isoxazolidone compounds for facilitation of perceptual learning
12/05/2002	US20020183369 For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis
12/05/2002	US20020183368 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183366 Cyclooxygenase-2 inhibitors, compositions and methods of use
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183362 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
12/05/2002	US20020183361 Heterocyclic sulfonamide inhibitors of beta amyloid production
12/05/2002	US20020183360 Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels
12/05/2002	US20020183359 Ophthalmic composition
12/05/2002	US20020183357 Therapy of stress urinary incontinence by administering a compound that is an alpha 1A adrenoceptor agonist and an alpha 1B antagonist
12/05/2002	US20020183356 Local anesthetic methods and kits
12/05/2002	US20020183354 For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders
12/05/2002	US20020183353 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse
12/05/2002	US20020183352 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
12/05/2002	US20020183351 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse
12/05/2002	US20020183350 Phenanthridine-n-oxides with pde-iv inhibiting activity
12/05/2002	US20020183349 For therapy and prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea
12/05/2002	US20020183347 For use in therapy of respiratory tract diseases
12/05/2002	US20020183346 Tricyclic androgen receptor modulator compounds and methods
12/05/2002	US20020183345 Administering to a drug naive human patient in need of treatment, as first line therapy, a low dose of a combination of metformin and glyburide
12/05/2002	US20020183344 Inhibition of cytokine generation
12/05/2002	US20020183343 Ultrashort-acting opioids for transdermal application

1 ... 5629 5630 5631 5632 5633 5634 5635 5636 5637 5638 5639 5640 5641 5642 5643 5644 5645 5646 5647 5648 5649 ... 7860